Challenges and Solutions to Implementation of Chimeric Antigen Receptor Therapies in Acute Myeloid Leukemia
European Journal of Haematology · 2026
DOI: 10.1111/ejh.70120 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Shivahamy Maheswaran und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine - Division of Hematology/Oncology, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, Massachusetts, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 82 Literaturangaben.
Abstract (Originalsprache)
The field of acute myeloid leukemia (AML) therapeutics has seen significant progress with respect to the development of targeted agents for specific mutational subsets. However, outcomes for patients with high‐risk AML remain dismal, and curative intent therapy is often challenging to administer in this population. AML is a highly plastic entity that employs a variety of mechanisms to circumvent immunosurveillance. In the recent decade, preclinical evidence for chimeric antigen receptor‐T (CAR‐T) and chimeric antigen receptor‐natural killer (CAR‐NK) therapies has gained traction in a variety of other hematologic malignancies, but the translation of these therapies to patients with AML has been limited. In this review, we discuss contemporary challenges to the clinical translation of cell‐based therapeutics in AML. We underscore practical solutions to facilitating the clinical availability of novel cell‐based therapies in AML. These solutions include widening the narrow therapeutic window through better myeloid‐specific CAR target validation, developing multi‐antigen or tandem CAR products, optimizing the immune repertoire and bone marrow niche in AML, and enhancing scalability of cell‐based therapeutics such that patients in local communities can benefit from ongoing efforts. These strategies may help improve the translational success of CAR‐T and CAR‐NK therapies in AML in the coming years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine - Division of Hematology/Oncology, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, Massachusetts, USA.
- Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Center for Clinical and Translational Science, UMass Chan Medical School, Worcester, Massachusetts, USA.
- Cancer Biology Program, Morningside Graduate School of Biomedical Sciences, UMass Chan Medical School, Worcester, Massachusetts, USA.
ORCID-Profile: Evan C Chen, Shyam A Patel
Zitieren
APA
Maheswaran, S., Gordon, C. D., Chen, E. C., & Patel, S. A. (2026). Challenges and Solutions to Implementation of Chimeric Antigen Receptor Therapies in Acute Myeloid Leukemia. European Journal of Haematology. https://doi.org/10.1111/ejh.70120
Vancouver
Maheswaran S, Gordon CD, Chen EC, Patel SA. Challenges and Solutions to Implementation of Chimeric Antigen Receptor Therapies in Acute Myeloid Leukemia. European Journal of Haematology. 2026. doi:10.1111/ejh.70120
BibTeX
@article{Maheswaran2026,
author = {Maheswaran, Shivahamy and Gordon, Caroline D and Chen, Evan C and Patel, Shyam A},
title = {Challenges and Solutions to Implementation of Chimeric Antigen Receptor Therapies in Acute Myeloid Leukemia},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70120}
}
EUVIMED